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Abstract
Background: The consent process for a genetic study is challenging when the research is conducted in
a group stigmatized because of beliefs that the disease is familial. Podoconiosis, also known as 'mossy foot',
is an example of such a disease. It is a condition resulting in swelling of the lower legs among people
exposed to red clay soil. It is a very stigmatizing problem in endemic areas of Ethiopia because of the widely
held opinion that the disease runs in families and is untreatable. The aim of this study was to explore the
impact of social stigma on the process of obtaining consent for a study on the genetics of podoconiosis in
Southern Ethiopia.
Methods: We adapted a rapid assessment tool validated in The Gambia. The methodology was qualitative
involving focus-group discussions (n = 4) and in-depth interviews (n = 25) with community members,
fieldworkers, researchers and staff of the Mossy Foot Treatment and Prevention Association (MFTPA)
working on prevention and treatment of podoconiosis.
Results: We found that patients were afraid of participation in a genetic study for fear the study might
aggravate stigmatization by publicizing the familial nature of the disease. The MFTPA was also concerned
that discussion about the familial nature of podoconiosis would disappoint patients and would threaten the
trust they have in the organization. In addition, participants of the rapid assessment stressed that the
genetic study should be approved at family level before prospective participants are approached for
consent. Based on this feedback, we developed and implemented a consent process involving community
consensus and education of fieldworkers, community members and health workers. In addition, we utilized
the experience and established trust of the MFTPA to diminish the perceived risk.
Conclusion: The study showed that the consent process developed based on issues highlighted in the
rapid assessment facilitated recruitment of participants and increased their confidence that the genetic
research would not fuel stigma. Therefore, investigators must seek to assess and address risks of research
from prospective participants' perspectives. This involves understanding the issues in the society, the
culture, community dialogues and developing a consent process that takes all these into consideration.
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Current national and international guidelines and regula-
tions on research ethics stress the importance of consent
as a requirement for conducting ethically sound research.
The assumptions underlying the practice of informed con-
sent include that decisions about research participation
should be both appropriately informed and voluntary,
and be made by someone competent to reach such deci-
sions [1,2].
Currently, there is widespread discussion and debate
about some aspects of informed consent. Among these
issues are the role of social and cultural factors in commu-
nicating research information and in the style of decision-
making about research participation; whether informed
consent should be obtained from all study subjects; and
whether one standard consent form should be used [3-8].
Additional issues have to be considered when genetic
research is conducted. Studies showed that individual-
based informed consent model may not be fully applica-
ble to genetic family studies in which the family is used as
the unit of analysis [9,10]. In family-based genetic studies,
individual participants are linked to other family mem-
bers through blood relationships, and family members
may become part of the study without their consent since
the results of the study may affect the whole family [11].
The consent process for genetic research becomes more
complex when research is conducted among a group that
is stigmatized because of the genetic nature of the disease
under investigation. Podoconiosis is an example of such a
disease. Podoconiosis (non-filarial elephantiasis) is a
chronic geochemical disease caused by long-term expo-
sure of feet to red clay soils of volcanic origin resulting in
progressive swelling of the lower legs. A recent genetic
study that enrolled 59 multi-generational and multiply
affected families presented evidence for a genetic basis to
podoconiosis. The sibling recurrence risk ratio was calcu-
lated to be 5.07, and heritability of podoconiosis with
proband ascertainment was estimated to be 62.9% (SE
0.069, p = 1 × 10-7). Segregation analysis showed the most
parsimonious model to be that of an autosomal co-dom-
inant major gene with age and foot wear as significant
environmental covariates [12]. It affects more than 5% of
the population in the Wolaita zone of southern Ethiopia.
According to a survey, in 2002 there were at least 81,000
podoconiosis patients in this zone that has an estimated
population of 1.6 million making the weighted zonal
prevalence 5.5% [13]. The disease affects the productive
segment of the population and results in an estimated loss
of 1.6 million US dollars every year in the Wolaita zone
[14]. A recent study indicated that 55.8% of community
respondents in the zone had at least one stigmatizing atti-
tude towards podoconiosis patients [15]. The main pre-
ventive measure for the disease is wearing protective shoes
and washing feet regularly since early childhood. In addi-
tion, personal hygiene, wearing protective boots and elas-
tic bandages, and elevation help reverse the swelling in
the earlier stages. Even if there are effective preventive
measures against podoconiosis, public health interven-
tion programs in Ethiopia target their resources on health
problems like TB, HIV/AIDS and malaria. The genetic
study on podoconiosis opens the door for targeting avail-
able scarce resources for education programs, provision of
shoes, socks and water supply to susceptible families that
are most at risk of having the disease.
People affected by podoconiosis in Wolaita zone are cared
for primarily by the Mossy Foot Treatment and Prevention
Association (MFTPA). The MFTPA is a local non-govern-
mental organization involved in prevention, treatment
and control of podoconiosis, and economic rehabilitation
of affected people through micro-financing activities. It
has established long standing relationships with the
podoconiosis community in Wolaita zone. The MFTPA
has developed strategies that facilitate trust among
affected people who are sceptical of being stigmatized by
the unaffected. A key component of these strategies
involves the deployment of treated podoconiosis patients
back into their communities after training as health edu-
cators by the MFTPA. These fieldworkers serve as role
models for the remaining podoconiosis-affected commu-
nity, and are socially accepted because they belong to the
community. Their activities include health education,
treatment, recruitment and counselling of patients
through home visits; creating networks with governmen-
tal sectors; and educating non-affected members of the
population. Currently, the organization treats more than
30,000 patients per year through 15 outreach clinics. The
treatment provided by the organization is simple and
effective in reversing progression of early stage disease. A
recent study shows that there is an improvement in the
quality of life of patients treated under the MFTPA [16].
Furthermore, many patients resume productivity after
treatment. These achievements contributed to the reduc-
tion of stigma because unaffected members of the com-
munity observed that the disease can be treated (Interview
with MFTPA staff).
Because of its high prevalence, and social, psychological
and economic impact, podoconiosis is a health problem
of public health importance in endemic areas. Affected
patients and families are illiterate and extremely poor. In
addition, the disease clusters within families making
affected families targets for social stigmatization. Affected
persons suffer from various forms of stigma manifested
during marital and social events, employment, and
schooling [17]. The stigma linked with having podoconi-
osis is so deep rooted that it plays a central role in manyPage 2 of 10
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looks at the familial component of the disease that is the
main cause of stigmatization, and may entail risk of
increasing stigma. As a consequence, there is need to iden-
tify a sensitive way to approach this population that has
been historically stigmatized and minimise potential
increase in stigma as a result of conducting the genetic
study. Obtaining consent from podoconiosis patients and
enrolling them in genetic research entails prior under-
standing of how the prevailing stigma shapes their fears
and concerns, and the way they make choices. This proc-
ess of understanding allows researchers to design appro-
priate consent processes for the local context. The rapid
assessment was designed to provide information about
this and findings were used to inform the design of the
consent process for the genetic study.
In this paper, we describe the development, implementa-
tion and interpretation of a rapid assessment in identify-
ing the manifestations of stigma in podoconiosis affected
families; the role of stigma in decision-making about par-
ticipation in family-based genetic research; and the inter-
action between stigma and participants' trust in
investigators and local institutions in making decisions
for research participation. The information gathered facil-
itated the design and implementation of the consent proc-
ess subsequently used in an international collaborative
study on the genetic basis of susceptibility to podoconio-
sis using data from affected sibling pairs, their biological
parents and unaffected controls.
Methods
Study area and design
The study was conducted in Wolaita zone which is located
in Southern Ethiopia covering a total area of 4541 sq.
kms. The methodology was entirely qualitative involving
focus group discussions (FGDs) and in-depth interviews
(IDIs). We used qualitative methodology because the pri-
mary purpose of the study is to explore the views, perspec-
tives, experiences, preferences and concerns of the study
participants. The study was conducted using semi-struc-
tured interview guides adapted from a rapid assessment
method validated in The Gambia [18]. The study instru-
ments included topics on perception of the community
about podoconiosis and manifestations of stigma associ-
ated with the disease; issues and concerns of the MFTPA
about genetic research on podoconiosis; and how stigma
impacts motivation and decision making pattern of par-
ticipants for genetic research. Pilot testing of the instru-
ments was done with one researcher in the United
Kingdom and a fieldworker and community member in
Wolaita.
Sampling
Generally, sampling was purposive based on pre-defined
inclusion criteria for enrolling participants. IDIs and
FGDs were conducted until no new relevant ideas
emerged from further interviews or discussions. The study
targeted four groups of participants. The first group incor-
porated scientists and researchers that had experience
working in Wolaita Zone on genetics or other biomedical
studies. IDIs were conducted with four scientists and
researchers in this phase of the study. The second group
included trained MFTPA fieldworkers. IDIs were con-
ducted with three social and counselling workers and four
health workers. The third group involved IDIs with (i) two
individuals involved in the administration and coordina-
tion of the activities of the MFTPA, (ii) two heads of kebele
(the smallest administrative unit/village in Ethiopia) and
(iii) two community leaders. The fourth group comprised
community residents of both sexes and included patients
and healthy subjects. In total 32 community members
participated, 8 in IDIs and 24 in 4 FGDs.
Data collection
With the exception of the community interviews, data
were collected by one of the principal investigators. An
experienced Masters in Public Health graduate who
speaks Wolaitigna (the local language) did the IDIs and
moderated the FGDs with community members. Before
conducting the IDIs and FGDs, he was trained about the
purpose of the study, the data collection instruments and
interviewing techniques.
Data analysis
Audiotapes were transcribed anonymously, and inter-
views conducted in Amharic and Wolaitigna were trans-
lated into English. During translation, we tried to keep
phrases and words as in the spoken language. However,
we acknowledge that some information carried by cultur-
ally flavoured phrases could be lost when expressions spo-
ken in the local languages were translated into written
English style. Data were imported into OpenCode soft-
ware v.2.1 (a freely available computer program for man-
aging and analyzing text data) [19]. Open coding was
used to identify themes that were developed into concep-
tual categories. Data were iteratively examined to identify
additional themes. The issues that arose fell into the fol-
lowing primary thematic domains: stigma associated with
podoconiosis; issues related to genetic research; role of
stigma in risk perception, motivation and decision mak-
ing for participation in genetic research; and place of trust
in the consent process.
Ethical considerations
The ethical review board of the Faculty of Medicine, Addis
Ababa University and the Ethiopian Science and Technol-
ogy Agency approved the study. Informed verbal consentPage 3 of 10
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ing the interviews and discussions. The consent process
was audio-taped for record purposes. Discussions and
interviews were conducted in settings that ensure partici-
pants' privacy.
Results
Overall, 46 individuals (27 males and 19 females) partic-
ipated in the study. Half of the community FGD partici-
pants, half of the researchers and one of the fieldworkers
interviewed were females. All interviewees from MFTPA
management and kebele offices were males. The age of the
respondents ranged between 23 and 70 years. The educa-
tional status of the fieldworkers ranged between early sec-
ondary level and college level education. Most of the
community interviewees had had no formal education.
Social stigma associated with podoconiosis
There were considerable variations among community
members' understanding of the causes of podoconiosis
including genetic susceptibility, snakebite, direct contact
of feet with clay soil, contagious, curses from God and
poor nutrition. Other less commonly mentioned reasons
were injuries (e.g., cut with axe), exposure to condensa-
tion, washing feet in hot weather and the evil eye. Genetic
susceptibility was the most frequently reported cause of
podoconiosis and this belief was observed to play a cen-
tral role in stigmatization of podoconiosis affected fami-
lies.
Participants from the community unanimously described
podoconiosis as a condition that results in debility, poor
self-confidence, social isolation and poverty. The local
vernacular term for podoconiosis is gediya kita, which
means leg swelling and is used as a derogatory term.
Stigma against podoconiosis patients is multi-faceted and
extensive. Manifestations of the stigma commonly men-
tioned by participants were (1) unwillingness to marry a
diseased person or anyone from a podoconiosis-affected
family; (2) shunning of patients and family members; (3)
avoiding physical contact with patients; (4) excluding
patients from social events like weddings and funerals; (5)
spitting on patients; (6) pinching nose when walking past
patients at a distance; (7) unwillingness of classmates to
sit with patients at the same desk in school; and (8)
unwillingness of unaffected family members to approach
an affected household member. Consequentially, patients
feel guilty, hide and isolate themselves from the rest of the
community members. Most patients described it as 'the
worst disease' mainly due to its negative social conse-
quences and absence of an effective cure at the advanced
stage.
In my opinion this is the worst of all diseases. It is bet-
ter to die than catching this disease because it keeps
you at home and you starve and thirst while you are
alive. [Male participant]
It breaks the social bond even with loving friends.
[Female participant]
They see people from leg to head, not up down. A
healthy person never likes to marry a podoconiosis
patient. An unaffected lady never likes to marry a
podoconiosis-affected man. [Fieldworker]
We also found that stigma impacts treatment seeking
behaviour. When asked why some affected patients do not
go to the MFTPA treatment centres, participants said
either that they despaired about their problem or that they
feared the discriminatory label given to them as 'foot
patients' when other people see them going to the centre.
In addition, they mentioned that some young patients do
not like to wear the distinctive and rather clumsy shoes
locally produced by the MFTPA because they mark them
out as having podoconiosis and target them for social
stigma.
We pray that people defeat their fears. Some we know
them heavily affected, but do not like to come because
they become afraid of others. They say, 'what will oth-
ers say about me?' People know they are patients or
there are rumours their children's legs for example are
swollen. I cannot understand why they are afraid.
[Male participant]
The shoes are also known by everyone, they say 'their
shoes'. Some pay their money to buy the shoes, they
not wear them in public places because people say he
is a patient. [Male participant]
As a consequence, podoconiosis patients do not like to
share information about their health problem with non-
affected people for fear it will fuel the stigma. Patients
need time to establish trust with researchers to ensure the
information they provide is kept confidential. As would
be expected, fieldworkers observed that this lack of trust
represents a potential barrier to obtaining consent and
genuine information from podoconiosis patients.
I am not happy when other people know about my
disease. Why should I tell people who undermine?
Why should I make those people laugh at me? I tell
people like you because I can be helped and cured.
[Female participant]
Yes, I mind people knowing about my health problem
because people insult and stigmatize us. I would not
have given you this interview if there had been some-
one else. [Male participant]Page 4 of 10
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them. Therefore, I will tell people like you if I have to
tell. I am not happy telling other people. [Female par-
ticipant]
Because of the long-term effects of the diseasein result-
ing in stigma and isolation of patients from the rest of
the community, affected people hesitate to confi-
dently talk, discuss and disclose their private issues.
This is one thing that we are usually in difficulty.
[MFTPA staff]
Patients demonstrated great trust in the MFTPA staff and
preferred to be approached by MFTPA staff if information
about their condition was sought. This is because MFTPA
fieldworkers are former podoconiosis patients and, more
importantly, they fully understood the social implications
if confidentiality was not maintained during treatment or
research.
They [MFTPA fieldworkers] are giving us a good serv-
ice, they give us education, they monitor our progress,
they give us shoes and under God they give us treat-
ment. They also keep our secret that is why right now
I am telling you the truth. [Male participant]
Established trust in the MFTPA and concerns of genetic 
research
The MFTPA was greatly trusted by podoconiosis patients
because of the services it provided and the strategy it fol-
lowed. The MFTPA mainly targeted interventions against
environmental triggers for the disease, primarily preven-
tion of long term exposure of feet to irritant clay soil.
Patients said the treatment provided improved their
health status and positively changed the attitude of others
towards podoconiosis patients, and hence contributed to
reduction of stigma. They also had confidence in the field-
workers because they are former podoconiosis patients
and are trusted that they work for the good of those
affected.
People used to believe we are hopeless, and the disease
cannot be prevented or treated. They never like to
marry our women even if they are beautiful. This
organization is a gift from God. Now things are chang-
ing. For example, [name of a female fieldworker] is
married to non-affected man. She earns good salary,
even better than I do. They have two children and live
a happy life. There are also other stories like this.
[Fieldworker]
Thanks to God! Previously even my friend was spitting
on me when my legs were swollen and smelling bad,
but now I am equal with other friends of mine. I can
say MFTPA is sent to me from God. Look at my leg it
is good now; previously it was deformed; it reached
this stage with MFTPA drugs and shoes. [Female par-
ticipant]
However, the MFTPA had not mentioned familial factors
in its communication with patients prior to the rapid
assessment being conducted. MFTPA staff were concerned
that raising the issue of genetics as a factor in the causation
of podoconiosis might erode the Association's relation-
ship with the podoconiosis community. They said that
overemphasis on the genetic component of podoconiosis
might disappoint patients and families who had already
been targets of stigmatization in the community because
of the prevailing belief that the disease is familial. They
said that patients would be comfortable if we simply tell
them, 'we do this study to understand more about the dis-
ease', and they suggested not mentioning specifically that
we were conducting genetic research.
It is difficult to talk about genetics among podoconio-
sis patients. Most of them do not like to hear that the
disease is familial. And we do not focus on that part.
We teach them that exposure to the soil is the cause of
the problem. They have seen that protection of feet
from the soil is preventive and helps in treating early
stage disease. They accepted this, and talking about
genetics may confuse them. That is what unaffected
people say, and our patients do not like to hear it from
us. [MFTPA staff]
Issues related to genetic research
In Wolaita, people are aware, to some extent, of what
genetic predisposition means. However, there is no equiv-
alent local term that precisely translates the word "genet-
ics". The community commonly uses expressions like
'dabuwan adhiya harigiya' (passed from parents and grand-
parents),'have it in the family', 'blood', 'bone', among
others when they refer to genetic causation.
We found that most patients believe that podoconiosis
runs in families. However, they do not have a clear under-
standing of patterns of occurrence of inherited diseases.
They think that if a disease is genetic, it must be manifest
in every member of the household, and should appear in
every generation of the family. Any deviation from this
(which is not the real heritability pattern of podoconiosis)
is thought to cast doubt on the heritability (i.e., genetic
nature) of the condition as expressed below:
This disease is not familial, if it was familial why my
mother and I suffer from the disease while her parents
were free of the disease. We probably acquired it due
to lack of care for our feet. That is the way the disease
catches one self. [Male participant]Page 5 of 10
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from either side of my parents; it was sudden when it
caught me. [Male participant]
Despite believing that podoconiosis is familial, the bur-
den of the stigma associated with the disease makes many
patients deny the heritability of the disease and pretend
that the disease is not present in their bloodline. Some
patients were irritated when the issue of genetics was
raised in discussions about podoconiosis. This response is
understandable given the fact that in Wolaita, as in most
parts of Ethiopia, family (bloodline relationship) has a
strong social value. If a family is thought to have some fac-
tor that has negative social value, the 'blood' (or gene) of
that family is considered 'unclean' (or susceptible) and
thus, for example, ineligible for marriage.
Researchers who participated in this study also expressed
their concern that some patients may be hesitant to partic-
ipate in genetic studies for fear it would fuel stigma
against them. Fieldworkers also said that even though
families are willing to participate, they could under-report
occurrence of the disease in their family line.
We know families with more than five affected mem-
bers. Even such families do not like to hear that the
disease is familial. This is partly because people who
do not have the problem attribute the disease to famil-
ial factors and stigmatize them. [Fieldworker]
A solution suggested for this was selective recruitment for
the genetic study of people thought to be genuine in pro-
viding such sensitive data, involving MFTPA fieldworkers
and cross-checking information gained from a family with
that obtained from other people who know the family
without compromising the confidentiality and privacy of
study participants.
Let alone this problem which is regarded as taboo in
social life, when we mobilize them for less sensitive
issues like income generating schemes, we talk to
them repeatedly. It is usually after such repetitions and
after convincing them that we will be able to touch
their heart. [MFTPA staff]
A person who was leading a miserable life for a long
period....one that was being discriminated against
would definitely need longer to trust people and pro-
vide genuine personal information to researchers.
[MFTPA staff]
Role of stigma in risk perception and motivation for 
participating
We found stigma to be of central importance to partici-
pants in evaluating both the risk and long term benefit of
participation in genetic research. Participants appreciated
that we proposed to collect a saliva sample and that the
procedure entailed no physical risk. The risk that had con-
siderable weight was the perceived negative social out-
come of the research. Patients were concerned that the
research might publicize podoconiosis as a familial condi-
tion and would aggravate the stigma by labelling children
of affected families as 'at-risk'. This was considered to have
potentially undesirable outcomes for their self-image and
perceived ability to shape their future. Fieldworkers
stressed that the feared social risks should be addressed by
the investigators before people are asked to consent to
participate in the study. Researchers suggested addressing
these concerns through a consultative dialogue between
researchers and the community.
Okay, let me say my family, my neighbours and others
coming here for treatment participated in your study.
I am very old and will no longer worry about myself.
If you say the disease is familial, my daughters will be
worried day and night. Who will marry them? Every-
one becomes afraid that the disease will catch her one
day. Do you have solution for us? [Female participant]
Stigma also shaped the motivation of participants and
their expectations of the long-term social outcome of the
genetic research. Some wondered whether the research
might restore their social position either by proving that
podoconiosis is not familial or by providing means of
developing drugs that cut transmission along generations.
Provided the social risks were addressed, most patients
were willing to participate in the genetic study even when
we explained that participation would have no immediate
benefit. Moreover, many patients were interested to know
why there were variations among families in the pattern of
occurrence of podoconiosis. Some participants com-
mented that whereas the 'nodular' form of the disease
seemed to run in families, the 'water bag' form did not
[20].
In contrast, a member of the MFTPA staff argued that
podoconiosis patients were keen to get an immediate
solution for their long-lived problem and do away with
the social stigma. He said this might constitute a barrier to
genetic research which would only benefit society in the
longer term.
Because these patients have been devoid of treatment
for many years, if we tell them that our research has no
immediate therapeutic benefit, it will discourage them
from participating because they will despair and asso-
ciate that with neglect of their problem.....we should
not discourage them that the [proposed genetic]
research has no immediate benefits. We should teach
them that every good medication starts from research.Page 6 of 10
(page number not for citation purposes)
BMC Medical Ethics 2009, 10:13 http://www.biomedcentral.com/1472-6939/10/13If they are told that research helps to improve treat-
ment, then they will be interested. [MFTPA staff]
Impact of stigma on decision making about genetic 
research participation
Participants of the rapid assessment agreed that the appro-
priate design of the consent process, and the patterns of
decision-making about participation at community, fam-
ily and individual levels would depend on the type of
study. Most participants said that patients are usually free
to make their own decisions about participation in
research. However, in relation to genetic research on
podoconiosis, most participants suggested involving the
head of the family, or the family as a whole in the consent
process. Because of the prevailing stigma attached to a
podoconiosis affected family, they (by implication) pre-
ferred that the ownership of every sample for genetic study
should belong to the whole family. They were particularly
sensitive about disclosing information regarding familial
affection by podoconiosis. As a result, most participants
expressed interest in consulting their relatives and return-
ing with ideas before consenting. We found that these
views did not differ depending on the gender of the
patient.
Usually, they cooperate when they are asked for
research in group by fieldworkers, but when it comes
to decision to such [genetic] research, they would be
interested if they are given the opportunity to consult
their family. [Fieldworker]
Tendency to consult a husband/wife or any other per-
son does not mean that there is influence in making
decision. In this regard the concept of individual con-
sent is respected... It is just a norm in the context of the
study area, and that should be respected. [Researcher]
For routine research, I am the one who gives permis-
sion for all members of the family. In this case it
involves giving information about every household
member and descendants. Therefore, we like to dis-
cuss amongst ourselves whether or not to disclose
family secret. [Male participant, head of household]
Usually, for research that involves any family member,
particularly children, the father gives permission, as
males are usually head of households. However, your
study is sensitive. It supposes familial transmission
within a family. If I decide on behalf of my child, she
may be disappointed one day when she grows old if
the study touches the pride of her family. My older
parents, some alive, should be consulted before we
participate in a study that talks about the whole family
tree. [Female participant]
Discussion
Risk perception and trust
The study showed that the stigma associated with podoco-
niosis is serious and plays a considerable role in the con-
sent process of genetic research on podoconiosis.
Participants paid close attention to the potential social
risks of genetic research and thought that the study might
intensify the existing stigma. Participants were not only
concerned about the impact of participation on their fam-
ily, but about its overall impact on the larger podoconio-
sis community.
Researchers argue that the risks of some types of research
can accrue to members of groups beyond the direct partic-
ipants [21,22]. In agreement with findings that suggest
that past negative experiences are easily triggered [23], our
findings showed that fear of stigma and discrimination in
the podoconiosis community was triggered by the idea of
the proposed genetic research. As a result, managing per-
ceived and expected social risks would be important for
our genetic study, and is also relevant to the effectiveness
of large science programs such as genomics [22].
Even though community level information provision
(discussed below) helped lessen the perceived risks of the
study, participants mainly relied on their relationship
with the MFTPA whether to trust that the information pro-
vided about the proposed genetic study was genuine and
that the study would be non-stigmatizing. Other studies
have also shown that trust is an important factor for enrol-
ment in research [7,21,24,25]. It is essential that potential
participants trust information provided about systems to
protect confidentiality, freedom to withdraw and alterna-
tive options for those who refuse [26].
In addition, our study showed that fear of stigmatization
might limit the tendency of participants to provide genu-
ine information about the disease status of other family
members if they doubted the trustworthiness of the
researchers. This corroborates a study that shows that trust
affects participants' willingness to enrol in studies, and
their tendency to tell the truth after joining studies [26].
Family-level decision-making for genetic research
The study addressed the pattern of decision making in the
context of the social stigma borne by podoconiosis-
affected families. In genetic studies, family members of
participants may indirectly become part of a genetic study
without their consent and the results of the study may
affect the whole family [11]. This issue was critical in our
study because stigma was attached to the whole family of
patients and because patients considered that stigma
might intensify because of the study. As a result, partici-
pants insisted that the appropriateness of the study
should be evaluated at the level of the family before seek-Page 7 of 10
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given appropriate information and sufficient time to dis-
cuss it amongst themselves before individual participants
were approached to enrol into the research. These findings
corroborated others' that argue that the individual-based
informed consent model does not fit genetic studies in
which the family is the unit of analysis [9,10]. Including
families in the consent process of genetic family studies is
essential to ensure that informed decisions are made in
such studies [27] and that complex intra-household deci-
sion-making dynamics are respected as appropriate [28].
It should be understood, however, that familial approval
to participate in genetic research is preferred not because
individual decision-making is not the norm in Wolaita
like some African traditional communities [21]. People in
Wolaita insist that the right of any competent member of
a family to refuse participation in genetic research should
be respected, indicating the widely supported view that
group-level approval, though desirable, cannot be a proxy
for individual consent [1,7,8,29-33].
The actual design and conduct of the consent process
Our findings highlighted the need to design a consent
process that ensured that participants were not further
stigmatized and that explained the genetic component of
the research without undermining the established rela-
tionship of MFTPA with patients. Therefore, we developed
a strategy aimed at reaching consensus (i) with the MFTPA
over the design of a consent process to support partici-
pants' comprehension of the purpose of the genetic study;
and (ii) with fieldworkers and the community about the
strategies available to combat further stigmatization as a
result of the study.
We started by training MFTPA fieldworkers on the devel-
opment of podoconiosis among genetically susceptible
people exposed to red clay soils. The training emphasized
that people protected from the red soils were unlikely to
develop disease even if they were genetically susceptible.
In addition, we emphasized the effectiveness of simple
interventions like foot wear and hygiene. We illustrated
the discussion using the example of podoconiosis previ-
ously being common in countries of North Africa (Alge-
ria, Tunisia, Morocco and the Canary Islands) and Europe
(France, Ireland and Scotland), but now being eradicated
through the universal use of shoes [20]. We explained that
people from these populations may still have the genetic
factor that makes them susceptible, and might develop
the disease if they were exposed. In addition, we men-
tioned that non-symptomatic people in the community
may also carry the genetic factor. This simplified explana-
tion of the mixed role of both genetic and environmental
factors was understood by the fieldworkers.
Following this, we conducted community discussion fora
on issues related to the familial nature of podoconiosis,
about which there are a number of rumours which are
rarely discussed in public. Administrators and fieldwork-
ers of MFTPA held frequent discussions with the podoco-
niosis community during routine outreach clinic visits
and discussed the role of familial and environmental fac-
tors in the causation of the disease. Every discussion was
focused on the effectiveness of footwear and good per-
sonal hygiene both to prevent and to treat the early stages
of podoconiosis [34].
The process was enriched by suggestions from patients
that the education should also embrace non-affected
members of the community. Podoconiosis affected peo-
ple stressed that non-affected people should be informed
that the disease is preventable by wearing shoes even in
the presence of familial factors. As a result, we conducted
expanded health education programs to improve the
awareness of the unaffected community and health pro-
fessionals. An important aspect of the task was to reduce
stigma experienced by podoconiosis affected people and
their families. After the community sensitization and
feedback, the MFTPA started to openly discuss the possi-
ble heritability of the disease. In addition, it started
recruiting non-symptomatic children of affected families
as targets for preventive intervention.
Future plans include dissemination of the findings of the
genetic research to both affected and non-affected mem-
bers of the community. In addition, via the MFTPA, we
will continue to educate the whole community and stress
universal use of footwear to avoid a false sense of security
among currently unaffected families who may also be
genetically susceptible. Examples could be gained from
experience of community engagement strategies in Kilifi,
Kenya [35].
The strategy we used combined information on the con-
duct of research with provision of health education to
both patients and the presumed stigmatizing population
and yielded very satisfactory results. Our discussions with
the community and family appeared effective in dimin-
ishing the perceived risk of many people. Although we did
not formally evaluate the intervention, most participant
families indicated they no longer had concerns over
stigma during subsequent recruitment by fieldworkers. Of
more than 200 families approached, only three denied
that patients with clear signs of disease were affected. In-
depth inquiry by the research nurses revealed that the
daughters concealed their legs so that people did not
know they were patients. Their parents were afraid that
participation could disclose this secret and were not con-
vinced by the strategy available for keeping confidential-
ity. We also ensured that we had satisfactory collaborativePage 8 of 10
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it had built with the community [36].
Conclusion
The study showed that investigators must seek to assess
and address risks of research from prospective partici-
pants' perspectives. This involves understanding the issues
in the society, the culture, community dialogues and
developing a consent process that takes all these into con-
sideration. The rapid assessment enabled us to design an
appropriate and locally acceptable consent process for
genetic research which had the potential to aggravate stig-
matization experienced by patients. We also observed that
the interventions linked with the consent process facili-
tated recruitment of participants and increased their con-
fidence that the research would not fuel stigma. In
addition, the interventions enabled informed community
discussion of a topic previously subject to rumour and
supported MFPTA staff's ability to discuss familial aspects
of the study on an ongoing basis. The genetic study did
not have immediate therapeutic benefit to the study par-
ticipants, however, the rapid assessment helped bridge the
communication gap among unaffected individuals in the
community, affected families and the MFTPA in the effort
to prevent and treat the disease. The previous study on the
genetics of podoconiosis has also strengthened the ration-
ale for providing shoes for unaffected children of affected
families [12].
The results of the study are applicable to other stigmatiz-
ing genetic diseases with or without effective treatment.
Our findings show that the most important strategy in
conducting genetic research in such instances is appropri-
ately addressing the social influences, personal prefer-
ences and felt risks through counselling and education
prior to the conduct of the actual study. It also showed
that researchers should study and respect the decision
making pattern of a community and a family before
approaching individual participants for a genetic study.
We believe the findings have practical uses for biomedical
investigators and others interested in the consent process
of studies conducted in socially stigmatized diseases and
in research assumed to bear the risk of fuelling stigma
among groups.
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